Glenmark Pharmaceuticals Ltd 2024 Integrated Report
Company: Glenmark Pharmaceuticals Ltd
Sector: Manufacturing
Country: India
Year: 2024
Type: Integrated Report
Pages: 428
The report presents a FY 2024 integrated view of Glenmark's financial and six-capital performance, including consolidated revenue from operations of INR 118,130.97 million and a strong focus on innovation and global healthcare access. Sustainability disclosures cover materiality, ESG governance, resource use, waste, water, workforce diversity, and climate performance. The company reports Scope 1, 2, and 3 emissions of 15,455, 69,632, and 1,71,146 tCO2e, respectively, and has set a 35% absolute Scope 1 and 2 reduction target by FY 2035. DNV Business Assurance India Private Limited independently assured selected non-financial disclosures at a limited level.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.